Kurzfassung

An open-label, multicenter, phase I/IB trial evaluation the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with Atezolizumab in patients with relapsed or refractory B Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia